Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non ...

Fino Payments Bank posted a 27.5% decline in its net profit for Q2 FY26 to INR 15.3 Cr from INR 21.1 Cr in the same period ...

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL:Lasme-cel in ...

Huawei submitted more than 10,000 technical contributions and published over 1,000 academic papers in the past year.

The Central Council for Research in Homeopathy (CCRH), New Delhi, has announced CCRH Recruitment 2025 for various Group A, B, ...

Lifileucel shows a 25.6% objective response rate and 71.8% disease control rate in advanced nonsquamous NSCLC patients, ...

Holdings reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene ...

With its universal spectrum multiplier, Cohere Technologies is delivering value today while setting the stage for marquee 6G ...

Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsNicole RileyAmeet Mallik - CEO & DirectorMohamed ...

Q3 2025 Earnings Call Transcript November 10, 2025 ADC Therapeutics S.A. beats earnings expectations. Reported EPS is ...